An ongoing dialogue on HIV/AIDS, infectious diseases,
March 3rd, 2010
Ritonavir Tablets: Any Experience Out There Yet?
Ritonavir tablets have been approved, and are apparently now in pharmacies. The capsules will also remain available for the foreseeable future.
However, I haven’t switched anyone over from the capsules yet, and neither has anyone else in our practice.
Would be interested in hearing how it’s going so far — best news would be that the tablets are both more convenient and have fewer side effects, but we know from the switch to Kaletra tablets that the latter might not occur.
(Which surprised me, I have to admit — thought the tablets would be better tolerated, but it was about the same.)
So … if you’ve switched patients to from the capsules to the tablets, comment away!
Categories: HIV, Patient Care
Tags: antiretroviral therapy, HIV, ritonavir
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
2 Responses to “Ritonavir Tablets: Any Experience Out There Yet?”
Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- CROI 2024 Denver: Really Rapid Review
- Just as CROI Gets Ready to Start, an Important Change to the IAS-USA HIV Treatment Guidelines
- Variability in Consult Volume Is a Major Contributor to Trainee Stress — What’s the Solution?
- Think Again Before Sending Your Patient Home on Intravenous Vancomycin
- Learning the Names of HIV Drugs Is Horribly Difficult — Here’s Why
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
-
NEJM Journal Watch — Recent Infectious Disease Articles
- Does Preoperative Urine Culture Affect Incidence of Postoperative Infection?
- Bacterial Survival Under Antibiotic Selection Pressure: The Evasive End Run
- COVID-19 Vaccine Protects Against Multisystem Inflammatory Syndrome in Children
- What Is the Long-Term Effectiveness of Tuberculosis Preventive Therapy?
- No Evidence of Greater Stroke Risk with Bivalent COVID-19 Vaccines
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster
We have been using generic RTV tablet since 2-3 years in India and all the capsules have been withdrawn since then. The tolerance is good
Sanjay, thanks for the comment. I wonder how your generic ritonavir compares with the version now licensed in the USA.